Drug Profile
Fosdagrocorat
Alternative Names: PF-04171327; PF-4171327Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Amides; Anti-inflammatories; Antirheumatics; Phenanthrenes; Pyridines; Small molecules
- Mechanism of Action Glucocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 May 2016 Discontinued - Phase-II for Rheumatoid arthritis in USA, Czech Republic, China, Hungary, South Korea, Russia, Serbia, Singapore, Slovakia, Spain, Turkey, Ukraine, Taiwan, Bulgaria, Colombia, Germany, India, Malaysia, Mexico, Poland, Romania, South Africa (PO) (Pfizer pipeline, May 2016)
- 03 Sep 2015 Phase II development of fosdagrocorat is ongoing
- 01 Jun 2014 Pfizer completes a phase II trial in Rheumatoid arthritis in US, Bulgaria, Colombia, the Czech Republic, Germany, Hungary, India, South Korea, Malaysia, Mexico, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Spain and the Ukraine (NCT01393639)